Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.

Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA
Clin Cancer Res. 2006 12 (3 Pt 1): 839-44

PMID: 16467097 · DOI:10.1158/1078-0432.CCR-05-1846

MeSH Terms (22)

Adult Aged Aged, 80 and over Antineoplastic Agents Carcinoma, Non-Small-Cell Lung DNA Mutational Analysis ErbB Receptors Erlotinib Hydrochloride Exons Female Gefitinib Genotype Humans Lung Neoplasms Male Middle Aged Mutation Quinazolines Retrospective Studies Sensitivity and Specificity Survival Analysis Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities:

Links